Mednet Logo

Leukemia 2014 Sep 02

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.

View Paper

Related Questions

Would you change TKIs in a patient with Ph-Like or Ph-positive B cell ALL who relapses on therapy (along with giving relapse chemotherapy)?

1
1 Answers
Mednet Member
Mednet Member
Pediatric Hematology/Oncology · CHU Sainte-Justine

Mechanisms of resistance in Ph-like ALL have not been extensively studied and will definitively be an active area of research. Given the biological similarities between Ph+ ALL and Ph-like ALL, one could hypothesize that similar mechanisms of resistance could occur in both entities. Kinase domain (K...